"Sulfonamides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of compounds that contain the structure SO2NH2.
| Descriptor ID |
D013449
|
| MeSH Number(s) |
D02.065.884 D02.886.590.700
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sulfonamides".
Below are MeSH descriptors whose meaning is more specific than "Sulfonamides".
This graph shows the total number of publications written about "Sulfonamides" by people in this website by year, and whether "Sulfonamides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 |
| 1997 | 1 | 1 | 2 |
| 2000 | 4 | 2 | 6 |
| 2001 | 1 | 1 | 2 |
| 2002 | 4 | 0 | 4 |
| 2003 | 7 | 3 | 10 |
| 2004 | 2 | 2 | 4 |
| 2005 | 2 | 5 | 7 |
| 2006 | 4 | 6 | 10 |
| 2007 | 8 | 2 | 10 |
| 2008 | 8 | 3 | 11 |
| 2009 | 3 | 4 | 7 |
| 2010 | 3 | 3 | 6 |
| 2011 | 6 | 7 | 13 |
| 2012 | 9 | 2 | 11 |
| 2013 | 9 | 3 | 12 |
| 2014 | 9 | 6 | 15 |
| 2015 | 1 | 6 | 7 |
| 2016 | 6 | 4 | 10 |
| 2017 | 4 | 1 | 5 |
| 2018 | 3 | 1 | 4 |
| 2019 | 8 | 2 | 10 |
| 2020 | 5 | 4 | 9 |
| 2021 | 5 | 5 | 10 |
| 2022 | 0 | 5 | 5 |
| 2023 | 1 | 6 | 7 |
| 2024 | 7 | 4 | 11 |
| 2025 | 3 | 6 | 9 |
| 2026 | 4 | 3 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sulfonamides" by people in Profiles.
-
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model. J Clin Oncol. 2026 Sep; 44(25):2422-2434.
-
Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA. Am J Hematol. 2026 Sep; 101(9):2246-2257.
-
All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia. N Engl J Med. 2026 Jun 04; 394(21):2107-2116.
-
Therapeutic targeting of BCL-2 during CART cell production augments potency through non-apoptotic adaptive changes. Signal Transduct Target Ther. 2026 Apr 27; 11(1).
-
Sodium Channel Isoform Diversity Underlies Chamber-Specific Cardiac Excitability. Circ Res. 2026 Apr 24; 138(9):e328159.
-
Targeting Melanoma-Associated Fibroblasts to Overcome Cancer Stem Cell-Driven Drug Resistance. J Am Coll Surg. 2026 Apr 01; 242(4):761-771.
-
Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML. Blood. 2026 01 15; 147(3):276-289.
-
Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model. Leukemia. 2025 11; 39(11):2697-2707.
-
Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia. Nat Rev Clin Oncol. 2025 Nov; 22(11):847-868.
-
Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth. Mol Cancer Ther. 2025 Aug 01; 24(8):1252-1264.